

*The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.*

## **Proposal for resolution to authorize the board of directors regarding issues**

The board of directors of Alligator Bioscience AB, Reg. No. 556597-8201, proposes that the extraordinary general meeting on 25 November 2025 resolves to authorize the board of directors, for the time up until the next annual general meeting, at one or several occasions, with or without deviation from the shareholders' preferential rights and with or without provisions regarding contribution in kind, set-off or other conditions, to resolve to issue new ordinary shares, convertibles and/or warrants with right to convert into and subscribe for ordinary shares. The reason for why a deviation from the shareholders' preferential rights should be possible is to enable the company to be able to source working capital, to be able to extend the ownership base with one or more owners of strategic importance, to be able to execute acquisitions of companies or operating assets as well as to enable new issues to industrial partners within the framework of partnerships and alliances. The total number of ordinary shares that may be issued (alternatively be issued through conversion of convertibles and/or exercise of warrants) shall not exceed 20 per cent of the number of outstanding ordinary shares as per the date when the issue authorization is utilized for the first time.

In case the authorization is used for an issue with deviation from the shareholders' preferential rights, the issue shall be made on market terms.

The authorization corresponds to the authorization resolved at the Annual General Meeting on 7 May 2025 and will, after it has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket), will replace the previous authorization from the Annual General Meeting. The reason to why the board of directors is now proposing a new authorization is partly that the majority of the existing authorization has been utilized in connection with the completion of two directed issues in May 2025, and to adapt the new authorization to the number of outstanding ordinary shares in the company after the completion of the rights issue proposed for approval under item 8 in the notice.

---

For a valid resolution, the proposal must be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the meeting.

The company's CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office.

---

Lund in October 2025

The Board of Directors of Alligator Bioscience AB (publ)